目的 探讨丹参酮Ⅱ_A磺酸钠联合阿罗洛尔治疗不稳定型心绞痛的临床疗效。方法 选取2022年3月—2023年3月在武汉市中医医院进行诊治的不稳定型心绞痛患者185例，根据治疗方案差异将患者分成对照组（93例）和治疗组（92例）。对照组患者口服盐酸阿罗洛尔片，1片/次，2次/d；治疗组在对照组基础上静脉滴注丹参酮Ⅱ_A磺酸钠注射液，40 mg药物加入100 mL生理盐水，1次/d；两组患者均进行2周的治疗。观察两组患者临床疗效，比较治疗前后两组患者心功能指标左室收缩末径（LVESD）、左室射血分数（LVEF）和6 min步行距离，血清可溶性ST2（sST2）、心肌肌钙蛋白I（cTnI）、单核细胞趋化蛋白-1（MCP-1）、转化生长因子-β结合蛋白2（LTBP-2）和血管扩张刺激磷蛋白（VASP）水平，及心绞痛视觉模拟量表（VAS）评分和生活质量综合评定问卷（GQOLI-74）评分。结果 治疗后，对照组和治疗组临床总有效率分别为82.80%和97.83%，两组比较差异具有统计学意义（P＜0.05）。治疗后，两组患者心功能指标LVEF和6 min步行距离明显增加，而LVESD则明显下降（P＜0.05），且治疗组心功能相关指标改善更为明显（P＜0.05）。治疗后，两组患者血清sST2、cTnI、MCP-1、LTBP-2水平均明显降低，而VASP水平则明显升高（P＜0.05），且治疗组各指标改善更为明显（P＜0.05）。治疗后，两组患者心绞痛VAS评分明显降低，而GQOLI-74评分则明显升高（P＜0.05），且治疗组改善更明显（P＜0.05）。结论 丹参酮Ⅱ_A磺酸钠联合阿罗洛尔治疗不稳定型心绞痛疗效显著，不仅能够显著改善患者心功能和促进血清学指标的恢复，同时还能够提升患者生活质量。

Objective To explore the effectiveness of sulfotanshinone sodium combined with arotinolol in treatment of unstable angina pectoris. Methods Patients (185 cases) with unstable angina pectoris in Wuhan Hospital of Traditional Chinese Medicine from March 2022 to March 2023 were divided into control (93 cases) and treatment (92 cases) group based on different treatments. Patients in the control group were po administered with Arotinolol Hydrochloride Tablets, 1 tablet/time, twice daily. Patients in the treatment group were iv administered with Sulfotanshinone Sodium Injection on the basis of the control group, 40 mg added into normal saline 100 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical evaluations were evaluated, the cardiac function related indicators LVEF, LVESD and 6 min walking distance, the levels of serum sST2, cTnI, MCP-1, LTBP-2 and VASP, and the scores of VAS and GQOLI-74 in two groups before and after treatment were compared. Results After treatment, the clinical effective rates of the control group and the treatment group were 82.80% and 97.83% respectively, and the difference between the two groups was statistically significant (P < 0.05). After treatment, the indexes of LVEF and 6 min walking distance were significantly increased, while LVESD was significantly decreased in two groups (P < 0.05), and the related indexes ofcardiac function were improved more significantly in the treatment group (P < 0.05). After treatment, the serum levels of sST2, cTnI, MCP-1 and LTBP-2 were significantly decreased, while the level of VASP was significantly increased in two groups (P < 0.05), and the improvement of each index in the treatment group was more obvious (P < 0.05). After treatment, the VAS score of angina pectoris was significantly decreased, while the GQOLI-74 score was significantly increased in two groups (P < 0.05), and the improvement was more obvious in the treatment group (P < 0.05). Conclusion Sulfotanshinone Sodium Injection combined with aroprolol has significant therapeutic effects on unstable angina pectoris, which can not only significantly improve the cardiac function and promote the recovery of serological indexes, but also improve the quality of life of patients.

R972

湖北省自然科学基金资助项目（2022CFC002）